Accelerate Your Pathway to Partnerships in Asia MARCH 10-11, 2020 • TOKYO, JAPAN
Total Page：16
File Type：pdf, Size：1020Kb
Asia Tokyo International Conference 2020 Accelerate your Pathway to Partnerships in Asia MARCH 10-11, 2020 • TOKYO, JAPAN General Overview • Advisory Committee • Education and Conference Programming • Partnering • Sponsorship Opportunities • #BIOASIA20 • bio.org/asia The BIO Asia International Conference is an exclusive partnering forum that brings together the global biotechnology and pharmaceutical industry to explore licensing and investor engagement in the current Asia-Pacific business and policy environments. Event Attributes and Opportunities • Gain insights into the changes, challenges, and opportunities collaborations and funding opportunities with participating key opinion and policy leaders foresee for the Japanese companies; communicate directly with conference attendees; biotech market. and pre-schedule private, 30 minute One-on-One meetings to be conducted onsite. • Facilitate connections with strategic partners looking to invest, partner, or license in or license out, early to late-stage • Panel discussions will increase your understanding of, programs in your therapeutic area of focus. and interaction with, the Japanese biotech market, the political landscape in Japan, and its impact on this important Opportunity for organizations to deliver company • industry sector. presentations, providing increased visibility in front of a global audience of biotech and pharmaceutical companies, all • Network with government leaders, peers, investors, and interested in cross-border business development alliances and potential partners attending the conference and our exclusive research collaborations. welcome reception. • BIO One-on-One Partnering enables attendees to search • Exclusive sponsorship opportunities to showcase thought company and investor profiles, drug assets, products, leadership, elevate brand identity and maximize partnering and services in the biopharma industry; evaluate potential benefits with an elite audience. ATTENDANCE BY REGION WHO SHOULD ATTEND: • Drug development and discovery companies • Biopharmaceutical companies Asia 50% • Medical technology companies Europe 15%Other 4% • Universities and institutes North America 31% • Intellectual property and legal organizations • Investors and financial services providers • Bio-clusters and incubators • Government and public support agencies HIGHLIGHTS / STATISTICS FROM PRIOR YEAR 400+ 27 250+ 1,270+ 50 DELEGATES COUNTRIES COMPANIES BIO ONE-ON-ONE INNOVATIVE COMPANIES REPRESENTED PARTNERING MEETINGS FROM AROUND THE WORLD PRESENTING THEIR STORY CE NVESTOR 1 CO-HOSTED BY:#BIOASIA20 • bio.or® g/asia CONFERENCE 2019 Advisory Committee Each year, BIO assembles a group of industry thought leaders to help us shape the conference program and provide input on key topics and themes that deliver excellence for all attendees. HENRY CHEN, JD RYO KUBOTA, MD, PHD TED TANAKA Managing Partner, Delos Capital Representative Executive Partnering Consultant, Tanaka Officer, Chairman, President and International LLC Chief Executive Officer, Kubota Pharmaceutical Holdings Co., Ltd. PATRICK FLOCHEL BO LIU, PHD GIL VAN BOKKELEN, PHD Global Life Sciences Sector Principal, Venture Investments, Chairman and Chief Executive Leadership Team, Tokyo, Johnson & Johnson Development Officer, Athersys Ernst & Young Corporation – JJDC, Inc. (JJDC) KYLE HATHAWAY, PHD ARLENE MORRIS DAMIEN VILLENEUVE Director of Policy and Government Chief Executive Officer, Vice President, Business Relations, Asia Pacific, MSD, Merck Willow Advisors Development Asia-Pacific and Japan, Lupin APO HUANG, PHD KYLE MURPHY HAYATO WATANABE Secretary General, Taiwan Bio Managing Director and Founder, Vice President, Tokyo, Industry Organization KMG Japan Locust Walk TARO INABA TORU SEO, PHD DALE YAKIN Managing Partner, Remiges Senior Director, Head, External Managing Director, VelocityHealth Ventures R&D Innovation Japan, Worldwide Securities Research & Development, Pfizer, Inc. YUICHI IWAKI, MD, PHD BT SLINGSBY, MD, PHD, MPH TAKAFUMI YAMAMOTO President and Chief Executive CEO & Executive Director, Global Chief Executive Officer and Officer, MediciNova Health Innovative Technology President, TODAI TLO (GHIT) Fund AMY JACKSON CHARLES STACEY, MD Japan Representative, PhRMA Chief Executive Officer, Cerecin Apply to join the 2020 Committee by emailing your interest to [email protected] SHINICHIRO KOMOTO RAMI SUZUKI, PHD Partner, Eight Roads Senior Director, Head of Japan Business Development, The Janssen Pharmaceutical Companies, Johnson & Johnson CE NVESTOR 2 #BIOASIA20 • bio.org/asia CONFERENCE Education and Conference Programming General themes at the BIO Asia International Conference focus on deal-making trends in the Japanese market, adapting clinical trial strategies across regulatory regimes, and shifts in Asian investment patterns among different therapeutic development specialties. 2019 BIO ASIA CONFERENCE RECAP How is the Drug Pricing Reform Initiative Affecting Explaining CFIUS and New Investment Regulations Patient Access, Investment, and Innovation in the United States in Japan? Market participants were updated on the evolving national security The Japanese government is pursuing a series of policy reforms review process and its impact on the biotechnology industry, as well that affect the pricing of medicines involving new cost-effectiveness as how additional rules may impact future business development frameworks and other reimbursement guidelines that poorly align and investment opportunities. with the value of biotechnology innovations, many of which are already treating patients successfully in other countries. Biotech Incubator Business Models: Lessons and Needed Improvements Reshaping Tumor Microenvironments Corporate biopharmas have decades of experience with university via Immunotherapies collaborations and open incubator models that produce research The panelists discussed the next wave of innovation in and pre-clinical data, but disappointingly few new medicines. What immunotherapies—how tumor microenvironments develop to features of incubators create value and where should incubator create treatments able to demonstrate more durable effects on business model innovation go next? This panel will consider lessons shrinking tumors across wider ranges of patients. learned from different sized organizations in different geographies and therapeutic areas that have attempted to improve R&D with Turning RNA Interference Research into Medicines external collaborators. The approval of the first siRNA-based therapeutic this year has Using M&A for Data Advantages Beyond opened the door for companies to pursue expansion of this class of medicines. Deal activity, the progress of academics, and a favorable Product Pipelines regulatory environment in Japan have contributed to interest in the Takayuki Ooka, Partner, Valuation, Modeling & Economics, Ernst & field. The discussion included updates on current approaches and Young Transaction Advisory Services Co. led a conversation about techniques for this pipeline of therapeutics. domestic and international biopharma deal trends, pinpointing regional opportunities to specialize or build value though digitizing Bridging External Innovation and Internal R&D for R&D workflow. New Patient Therapies Strategic cross-border application of licensing agreements accelerates the path of an idea for a new medicine to get from the research laboratory to the patient needing treatment. CE NVESTOR 3 #BIOASIA20 • bio.org/asia CONFERENCE REPRESENTATIVE PROGRAM SPEAKERS Jun Bao, PhD Lindi Tan, PhD President and Chief Executive Officer Chief Financial Officer Impact Therapeutics Ascletis Pharma Inc. Michael Chan Masako Nakamura Head of International Issuer Business Head of Asia Hong Kong Exchanges and Clearing Limited (HKEX) Alnylam Pharmaceuticals President and Representative Director Niels Emmerich, PhD Alnylam Japan K.K. Vice President Global Head Search & Evaluation, AbbVie Gil Van Bokkelen, PhD Chairman and CEO Lei Gao, PhD Athersys Executive VP/Deputy GM Harbin Pharmaceutical Group Co., Ltd. Michael Wang, PhD Vice President China BD and Alliance Management Pingsheng Hu, PhD Brii Biosciences President and Chief Executive Officer Sinorda Biomedicine Ltd. Hayato Watanabe Partner Hardy TS Kagimoto, MD Locust Walk Chairman and CEO Healios K.K. Company Presentations The BIO Asia International Conference assembles U.S. and European drug development companies, as well as Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements. Presenting companies at the event are biopharmas ready to engage in cross-border partnerships and licensing discussions. Philanthropy 2% Multiple Discovery Products Other/Not Applicable 7% in Market 17% 5% Publicly Traded Company Pre-Clinical 21% 26% Development Types of Phase of Presenting Presenting Phase III 12% Companies Companies Phase II 12% Phase I Privately Funded Company 21% 74% CE NVESTOR 4 #BIOASIA20 • bio.org/asia CONFERENCE Partnering BIO One-on-One Partnering is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives. Musculoskeletal disorder 2% Ocular disease 2% Metabolic disorder 3% Genitourinary disease 3% Endocrine disease 4% Neoplasm Other CEO-level 11% 25% 20% Inflammatory disease 4% Neurological disease Primary 11% Seniority Level Other C-suite Respiratory disease 5%